• C4 Therapeutics posted Q2 revenue of USD 6.6 million, up 1.54% year over year, helped by revenue recognized under its new Roche DAC collaboration.
• Net loss narrowed to USD 23.6 million; loss per share improved to USD 0.18.
• R&D expense fell 6.49% to USD 24.5 million; G&A expense eased 2.27% to USD 8.6 million, both on lower stock-based compensation.
• Cash, cash equivalents and marketable securities rose to USD 300.4 million, reflecting USD 33.5 million of ATM proceeds and a USD 20 million Roche upfront payment.
• Phase 2 MOMENTUM enrollment remains on track to finish in Q1 2027; initial ORR data expected in 2H 2027, with additional cemsidomide combination updates slated for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807425) on August 11, 2026, and is solely responsible for the information contained therein.